Picture loading failed.

Anti-APP therapeutic antibody (Pre-made Solanezumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Solanezumab (proposed INN, LY2062430[1]) is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer's disease. The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-527-1mg 1mg 3090
GMP-Bios-ab-527-10mg 10mg 21890
GMP-Bios-ab-527-100mg 100mg 148000
GMP-Bios-ab-527-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-APP therapeutic antibody (Pre-made Solanezumab biosimilar,Whole mAb)
INN Name Solanezumab
TargetAPP
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI Structure4xxd:ED:BA
95-98% SI StructureNone
Year Proposed2008
Year Recommended2009
CompaniesEli Lilly
Conditions Approvedna
Conditions ActiveAlzheimer's disease
Conditions Discontinuedna
Development Techna